Medical Condition News

RSS

Teva Respiratory reports positive results from BDP HFA Nasal Aerosol Phase III trial in seasonal allergic rhinitis

Teva Respiratory today announced positive results from a Phase III trial evaluating the efficacy and safety of beclomethasone dipropionate (BDP) hydrofluoroalkane (HFA) Nasal Aerosol in the treatment of seasonal allergic rhinitis (SAR). The study met all efficacy endpoints, demonstrating a statistically significant benefit as compared to placebo. Furthermore, the safety profile of BDP HFA Nasal Aerosol was similar to placebo.

29 Jul 2010

Scientists study mutant protein lump formation process to control brain cell death

Australian scientists have identified the behaviour of the mutant protein 'huntingtin' which leads to the fatal Huntington's disease providing potential targets to treat the disease, a University of Melbourne study reveals.

29 Jul 2010

Boston Scientific announces launch of Neuroform EZ Stent System in U.S. and Europe

Boston Scientific Corporation today announced the U.S. and European launches of the Neuroform EZ(TM) Stent System, its fourth-generation intracranial aneurysm stent system designed for use in conjunction with endovascular coiling to treat wide-necked aneurysms. The Company plans to launch the product immediately in both markets.

29 Jul 2010

Athersys reports positive results from MultiStem phase I clinical trial in heart attack patients

Athersys, Inc. announced today positive results from its phase I clinical trial of MultiStem®, its allogeneic cell therapy product, administered to individuals following acute myocardial infarction (AMI), more commonly referred to as a heart attack. The study results, based on four months of post-treatment patient data, demonstrate that MultiStem was well tolerated at all dose levels and also suggest improvement in heart function in treated patients.

29 Jul 2010

Inhibition of MMPs can offer therapeutic benefit in Huntington's disease: Study

A new study reveals that an enzyme linked with multiple disorders is also involved in the generation of toxic, neuron-killing protein fragments in Huntington's disease (HD). The research, published by Cell Press in the July 29 issue of Neuron, provides insight into Huntington's pathology and proposes new therapeutic strategies for this devastating incurable disease.

29 Jul 2010

HemoBioTech receives patent for HemoTech treatment of acute blood loss

HemoBioTech announced today the issuance of a new patent US 7,759,306 B2, Methods of Treating Acute Blood Loss. HemoBioTech has an exclusive worldwide license from Texas Tech University to commercialize the technology. The new patent continues to May 16, 2026. The major advance in HemoTech is the presence of Adenosine which has anti-inflammatory activity.

29 Jul 2010

Kyowa Hakko Kirin initiates Phase 2 trial of ARQ 197 for gastric cancer: ArQule

ArQule, Inc. today announced the initiation of a Phase 2, single agent trial with ARQ 197 in gastric cancer by Kyowa Hakko Kirin, its exclusive licensee for the development and commercialization of ARQ 197 in the Asian territory consisting of Japan, China (including Hong Kong), South Korea and Taiwan. Initiation of this trial will trigger a $5 million milestone payment to ArQule from Kyowa Hakko Kirin.

28 Jul 2010

Researchers establish new criteria for liver transplantation

Researchers at the University of California, San Francisco propose that treatments used on liver cancers beyond the established Milan criteria for liver transplantation may be appropriate for all patients with hepatocellular carcinoma who are listed for transplantation. Full details appear in the August issue of Liver Transplantation, a journal published by Wiley-Blackwell on behalf of the American Association for the Study of Liver Diseases.

28 Jul 2010

Allos reports topline results from Phase 2b trial of FOLOTYN vs erlotinib in advanced NSCLC

Allos Therapeutics, Inc. today announced topline results from the Company's randomized Phase 2b investigational trial of FOLOTYN® (pralatrexate injection) versus erlotinib in patients with Stage IIIB/IV (advanced) non-small cell lung cancer (NSCLC) who had received one or two prior systemic treatments including at least one prior platinum-based regimen. The objective of the trial was to estimate the efficacy of FOLOTYN compared to that of erlotinib as assessed by overall survival.

28 Jul 2010

Price of sun overindulgence and tanning misuse is not just skin deep

It's what marketers lead us to believe is the picture of glowing health - the ultimate tan. But sun overindulgence and tanning misuse does have a price. And it's not just skin deep.

28 Jul 2010

Study of over 6,200 impairment ratings spanning 5 years reveals 78% error rate

A study of more than 6,200 impairment ratings spanning 5 years revealed an error rate of 78 percent, resulting in ratings averaging more than twice what was appropriate. Ratings from eight states were examined, with 81 percent of the cases being from California and 91% rated using the Fifth Edition of the American Medical Association Guides to the Evaluation of Permanent Impairment.

28 Jul 2010

New £50M fund made available to help patients get access to innovative new cancer drugs

The government has announced a new £50 million fund to improve access to cancer drugs until the new Cancer Drugs Fund comes into effect in April 2011.

28 Jul 2010

POA releases consensus statement on CIRS-WDB

Policyholders of America released a consensus statement written by treating physicians and researchers in the field on the mechanism and treatment of illness found in people sickened by exposure to water-damaged buildings. This illness has been the subject of heated debate that has resulted in harsh allegations being lobbed at patients by experts hired by industry to cast doubt on the legitimacy of the illness.

28 Jul 2010

Human insulin-producing beta cell replication sustained with single stimulatory molecule: Study

With a single stimulatory molecule, human insulin-producing beta cell replication can be sustained for at least four weeks in a mouse model of diabetes, according to researchers at the University of Pittsburgh School of Medicine in Diabetes, a journal of the American Diabetes Association.

28 Jul 2010

NEI, FDA to sponsor Glaucoma Endpoints conference

The National Eye Institute and the Food and Drug Administration are sponsoring a Glaucoma Endpoints conference on September 24, 2010, to develop definitions and standards for describing structural changes in the glaucomatous optic nerve and functional changes in vision, as criteria for approval of new glaucoma therapeutics in clinical trials. The one-day meeting will take place at the Natcher Center, National Institutes of Health in Bethesda, Md.

28 Jul 2010

Students with ADHD less likely to finish high school graduation: Study

Teens with attention-deficit/hyperactivity disorder - the most common childhood psychiatric condition in the United States - are less likely to finish high school on time than students with other mental-health disorders that often are considered more serious, a large national study by researchers at the UC Davis School of Medicine has found. The study found that nearly one third of students with ADHD, twice the proportion as students with no psychiatric disorder, either drop out or delay high school graduation.

28 Jul 2010

NCKU engineers and physical therapy experts develop rehabilitation robots

Prof. Ming-Shaung Ju of the Department of Mechanical Engineering at National Cheng Kung University (NCKU), Tainan, Taiwan, has developed rehabilitation robots by integrating the experience of physical therapy experts at NCKU Hospital, opening a new road for stroke patients' rehabilitation.

28 Jul 2010

Medtronic reports FDA Panel's affirmative votes on AMPLIFY rhBMP-2 Matrix for posterolateral spine fusion

The U.S. Food and Drug Administration (FDA) Orthopaedic and Rehabilitation Devices Panel today voted 9 for and 4 against (1 abstention) on safety and 10 for and 3 against (1 abstention) on effectiveness, that data including results from a large, prospective randomized clinical trial demonstrated the safety and effectiveness of AMPLIFY™ rhBMP-2 Matrix for fusions of the lower spine in patients with degenerative disc disease.

28 Jul 2010

NICE publishes new guideline to help improve care, treatment for patients with CUP

The National Institute for Health and Clinical Excellence has published a new guideline which should help to improve care for thousands of patients with advanced cancer that has spread from an unknown primary location.

28 Jul 2010

Gottlieb collaborates with Loyola Cancer Care to deliver world class university hospital expertise

Cancer patients at the Marjorie G. Weinberg Cancer Center, located on the Gottlieb Memorial Hospital campus, are now being seen by Loyola University Health System physicians.Loyola Cancer Care & Research at the Marjorie G. Weinberg Cancer Center offers patients the convenience of a community hospital and the expertise of a world-class university hospital.

28 Jul 2010

Medical Condition News

Teva Respiratory reports positive results from BDP HFA Nasal Aerosol Phase III trial in seasonal allergic rhinitis

Scientists study mutant protein lump formation process to control brain cell death

Boston Scientific announces launch of Neuroform EZ Stent System in U.S. and Europe

Athersys reports positive results from MultiStem phase I clinical trial in heart attack patients

Inhibition of MMPs can offer therapeutic benefit in Huntington's disease: Study

HemoBioTech receives patent for HemoTech treatment of acute blood loss

Kyowa Hakko Kirin initiates Phase 2 trial of ARQ 197 for gastric cancer: ArQule

Researchers establish new criteria for liver transplantation

Allos reports topline results from Phase 2b trial of FOLOTYN vs erlotinib in advanced NSCLC

Price of sun overindulgence and tanning misuse is not just skin deep

Study of over 6,200 impairment ratings spanning 5 years reveals 78% error rate

New £50M fund made available to help patients get access to innovative new cancer drugs

POA releases consensus statement on CIRS-WDB

Human insulin-producing beta cell replication sustained with single stimulatory molecule: Study

NEI, FDA to sponsor Glaucoma Endpoints conference

Students with ADHD less likely to finish high school graduation: Study

NCKU engineers and physical therapy experts develop rehabilitation robots

Medtronic reports FDA Panel's affirmative votes on AMPLIFY rhBMP-2 Matrix for posterolateral spine fusion

NICE publishes new guideline to help improve care, treatment for patients with CUP

Gottlieb collaborates with Loyola Cancer Care to deliver world class university hospital expertise

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Latest News